Diagnostic imaging in the preoperative management of lung cancer

Surgery Today

Volumn 44, Issue 7, 2014, Pages 1197-1206

  Imai, Kazuhiro ^a   Minamiya, Yoshihiro ^a   Saito, Hajime ^a   Motoyama, Satoru ^a   Sato, Yusuke ^a   Ito, Aki ^a   Yoshino, Kei ^a   Kudo, Satoshi ^a   Takashima, Shinogu ^a   Kawaharada, Yasushi ^a   Kurihara, Nobuyasu ^a   Orino, Kimito ^a   Ogawa, Jun Ichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Computed tomography; Lung cancer; Magnetic resonance imaging; Positron emission tomography; Preoperative management

Indexed keywords

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOBRONCHIAL ULTRASONOGRAPHY; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MINIMALLY INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; REVIEW; THORAX SURGERY; TRANSBRONCHIAL ASPIRATION; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; SECONDARY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903276156     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0660-z     Document Type: Review

References (83)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-7. (Pubitemid 27260107)
4. Fukui T, Mitsudomi T. Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment. Surg Today. 2010;40:191-8.
5. Sawabata N, Fujii Y, Asamura H, Nomori H, Nakanishi Y, Eguchi K, et al. Lung Cancer in Japan: analysis of Lung Cancer Registry for resected cases in 2004 (in Japanese). Jpn J Lung Cancer. 2010;50:875-88.
6. Downey RJ. Follow-up of patients with completely resected lung cancer. Chest. 1999;115:1487-98.
7. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg. 1994;8:37-42.
8. Van Schil P. The restaging issue. Lung Cancer. 2003;42(Suppl 1):S39-45. (Pubitemid 37378185)
9. Ueda K, Kaneda Y, Saeki K, Fujita N, Zempo N, Esato K. Hilar lymph nodes in N2 disease: survival analysis of patients with non-small cell lung cancers and regional lymph node metastasis. Surg Today. 2002;32:300-4. (Pubitemid 34671260)
10. Marra A, Hillejan L, Zaboura G, Fujimoto T, Greschuchna D, Stamatis G. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg. 2003;125:543-53. (Pubitemid 36373900)
11. Fujimoto T, Cassivi SD, Yang P, Barnes SA, Nichols FC, Deschamps C, et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg. 2006;132:499-506. (Pubitemid 44278877)
12. Miyoshi K, Mimura T, Iwanaga K, Adachi S, Tsubota N, Okada M. Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today. 2010;40:428-32.
13. Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012;81:988-1001.
14. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178-201.
15. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. American College of Chest Physicians. Invasive mediastinal staging of lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:202-20.
16. Akiba T, Marushima H, Harada J, Kobayashi S, Morikawa T. Importance of preoperative imaging with 64-row three-dimensional multidetector computed tomography for safer video-assisted thoracic surgery in lung cancer. Surg Today. 2009;39:844-7.
17. McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung: therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836-41. (Pubitemid 15012851)
18. Grillo HC. Technical considerations in stage III disease: pleural and chest wall involvement. In: Delarue NC, Eschapasse H, editors. International trends in general thoracic surgery, vol. 1st. Philadelphia: WB Saunders; 1985. p. 134-8.
19. Komaki R, Mountain CF, Holbert JM, Garden AS, Shallenberger R, Cox JD, et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys. 1990;19:31-6. (Pubitemid 20239781)
20. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIa disease. Chest. 1990;97:1045-51. (Pubitemid 20166788)
21. Kawaguchi K, Mori S, Usami N, Fukui T, Mitsudomi T, Yokoi K. Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. Lung Cancer. 2009;64:41-4.
22. Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
23. Travis WD, Brambilla E, Rami-Porta R, Vallières E, Tsuboi M, Rusch V, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1384-90.
24. Grenier P, Dubary B, Carette MF, Frija G, Musset D, Chastang C. Preoperative thoracic staging of lung cancer: CT and MR evaluation. Diagn Interv Radiol. 1989;1:23-8.
25. Uhrmeister P, Allmann KH, Wertzel H, Altehoefer C, Laubenberger J, Hasse J, et al. Chest wall infiltration by lung cancer: value of thin-sectional CT with different reconstruction algorithms. Eur Radiol. 1999;9:1304-9.
26. Higashino T, Ohno Y, Takenaka D, Watanabe H, Nogami M, Ohbayashi C, et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56:48-55. (Pubitemid 41316486)
27. Imai K, Minamiya Y, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. Use of CT to evaluate pleural invasion in nonsmall cell lung cancer: measurement of the ratio of the interface between tumor and neighboring structures to maximum tumor diameter. Radiology. 2013;267(2):619-26.
28. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29:26-9. (Pubitemid 41831343)
29. Staples CA, Müller NL, Miller RR, Evans KG, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988;167:367-72.
30. Lewis JW Jr, Pearlberg JL, Beute GH, Alpern M, Kvale PA, Gross BH, et al. Can computed tomography of the chest stage lung cancer? Yes and no. Ann Thorac Surg. 1990;49:591-5.
31. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol. 1985;144:261-5. (Pubitemid 15168325)
32. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990;141:1096-101. (Pubitemid 20172555)
33. Kramer H, Groen HJ. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg. 2003;238:180-8. (Pubitemid 38174491)
34. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999;213:530-6. (Pubitemid 29510603)
35. Imai K, Minamiya Y, Saito H, Nakagawa T, Hosono Y, Nanjo H, et al. Accuracy of helical computed tomography for the identification of lymph node metastasis in resectable non-small cell lung cancer. Surg Today. 2008;38:1083-90.
36. Ohno Y, Hatabu H, Takenaka D, Higashino T, Watanabe H, Ohbayashi C, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231:872-9. (Pubitemid 38668111)
37. Hochhegger B, Marchiori E, Sedlaczek O, Irion K, Heussel CP, Ley S, et al. MRI in lung cancer: a pictorial essay. Br J Radiol. 2011;84:661-8.
38. Sakai S, Murayama S, Murakami J, Hashiguchi N, Masuda K. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. J Comput Assist Tomogr. 1997;21:595-600. (Pubitemid 27432699)
39. Biederer J. General requirements of MRI of the lung and suggested standard protocols. In: Kauczor HU, editor. MRI of the lung. Berlin: Springer; 2009. p. 3-16.
40. Koyama H, Ohno Y, Kono A, Takenaka D, Maniwa Y, Nishimura Y, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18:2120-31.
41. Ohno Y, Koyama H, Dinkel J, Hintze C. Lung cancer. In: Kauczor HU, editor. MRI of the lung. Berlin: Springer; 2009. p. 179-216.
42. Ohno Y, Adachi S, Motoyama A, Kusumoto M, Hatabu H, Sugimura K, et al. Multiphase ECG triggered 3D contrast enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13:215-24. (Pubitemid 32066658)
43. Kajiwara N, Akata S, Uchida O, Usuda J, Ohira T, Kawate N, et al. Cine MRI enables better therapeutic planning than CT in cases of possible lung cancer chest wall invasion. Lung Cancer. 2010;69:203-8.
44. Akata S, Kajiwara N, Park J, Yoshimura M, Kakizaki D, Abe K, et al. Evaluation of chest wall invasion by lung cancer using respiratory dynamic MRI. J Med Imaging Radiat Oncol. 2008;52:36-9. (Pubitemid 351598471)
45. Shiotani S, Sugimura K, Sugihara M, Kawamitsu H, Yamauchi M, Yoshida M, et al. Diagnosis of chest wall invasion by lung cancer: useful criteria for exclusion of the possibility of chest wall invasion with MR imaging. Radiat Med. 2000;18:283-90.
46. Heelan RT, Demas BE, Caravelli JF, Martini N, Bains MS, McCormack PM, et al. Superior sulcus tumors: CT and MR imaging. Radiology. 1989;170:637-41. (Pubitemid 19062573)
47. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM. Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg. 2004;26:202-8.
48. Wittenberg KH, Adkins MC. MR imaging of nontraumatic brachial plexopathies: frequency and spectrum of findings. Radiographics. 2000;20:1023-32.
49. Fujimoto K, Edamitsu O, Meno S, Abe T, Honda N, Ogoh Y, et al. MR diagnosis for metastasis or non-metastasis of mediastinal and hilar lymph nodes in cases of primary lung cancer: detectability, signal intensity, and MR-pathologic correlation (in Japanese). Nihon Igaku Hoshasen Gakkai Zasshi. 1995;55: 162-71.
50. Takenaka D, Ohno Y, Hatabu H, Ohbayashi C, Yoshimura M, Ohkita Y, et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. Eur J Radiol. 2002;44:216-24. (Pubitemid 35430207)
51. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071-80. (Pubitemid 47548169)
52. Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer. 2008;60:62-8. (Pubitemid 351434459)
53. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Nonsmall cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632-42.
54. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007-15.
55. DiPerna CA, Wood DE. Surgical management of T3 and T4 lung cancer. Clin Cancer Res. 2005;11:5038-44.
56. Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. Biomed Biotechnol. 2012;2012:783739.
57. Takenaka T, Yano T, Morodomi Y, Ito K, Miura N, Kawano D, et al. Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography. Surg Today. 2012;42:934-9.
58. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-7. (Pubitemid 36706537)
59. Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770-6.
60. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-a-methyl tyrosine uptake in outcome of nonsmall cell lung cancer. Nucl Med Biol. 2010;37:911-6.
61. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18 F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep. 2001;8:337-9.
62. Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47-52. (Pubitemid 30407359)
63. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23-32. (Pubitemid 46063025)
64. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261-6. (Pubitemid 35341800)
65. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255-60. (Pubitemid 46123001)
66. Behzadi A, Ung Y, Lowe V, Deschamps C. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg. 2009;52:235-42.
67. Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6:1350-8.
68. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008;246:772-82.
69. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with nonsmall cell lung cancer. AJR Am J Roentgenol. 2000;175:245-9. (Pubitemid 30415572)
70. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918-24. (Pubitemid 36051125)
71. Toaff JS, Metser U, Gottfried M, Gur O, Deeb ME, Lievshitz G, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol. 2005;40:204-9. (Pubitemid 40393231)
72. Duysinx BC, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun. 2006;27:971-6. (Pubitemid 44706893)
73. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Nonsmall cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-9. (Pubitemid 41170866)
74. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (1 cm), intermediate (1 to 3 cm), and large (3 cm) lymph node lesions. Chest. 2000;117:773-8. (Pubitemid 30152219)
75. Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009;64:757-62.
76. Zhang R, Ying K, Shi L, Zhang L, Zhou L. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a metaanalysis. Eur J Cancer. 2013;49(8):1860-7.
77. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, et al. FDG PET for staging of advanced nonsmall cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging. 2002;29:804-8.
78. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002;43:752-6. (Pubitemid 34663295)
79. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:1357-60.
80. Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173-90.
81. Aquino SL, Asmuth JC, Alpert NM, Halpern EF, Fischman AJ. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration. J Comput Assist Tomogr. 2003;27:479-84. (Pubitemid 36935900)
82. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glu-cose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest. 2004;125:1413-23. (Pubitemid 38501358)
83. Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, Maldonado A, García de Barajas S, Calero-García R, et al. Accuracy of helical computed tomography and [18F] fluorode-oxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23:8348-56.